 |
市場調査レポート
商品コード
1455051
細胞バンクアウトソーシングの世界市場規模、シェア、成長分析、タイプ別、エンドユーザー別-産業予測、2024～2031年Global Cell Banking Outsourcing Market Size, Share, Growth Analysis, By Type(Master Cell Banking and Working Cell Banking), By End-User(Biopharmaceutical Companies and Contract Research Organizations (Cros).) - Industry Forecast 2024-2031 |
||||||
| 細胞バンクアウトソーシングの世界市場規模、シェア、成長分析、タイプ別、エンドユーザー別-産業予測、2024～2031年 |
|
出版日: 2024年03月17日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
細胞バンクアウトソーシングの世界市場規模は2022年に106億米ドルと評価され、2023年の123億4,000万米ドルから2031年には415億8,000万米ドルに成長し、予測期間中（2024～2031年）のCAGRは16.40%で成長する展望です。
世界の細胞バンクアウトソーシング市場は、さまざまな要因に後押しされ、今後数年間で大幅な成長を遂げる展望です。幹細胞治療の採用が拡大し、モノクローナル抗体や効率的なバイオ医薬品の需要が高まっていることに加え、凍結保存や細胞バンク調製における技術が進歩していることが大きな推進力となっています。CellTrials.orgが報告しているように、2020年第1四半期には、先進的な細胞治療における新たな臨床試験の世界の登録が30％近く急増し、細胞バンクサービスに対する需要が高まっていることは明らかです。さらに、政府の好意的な取り組みや、細胞株の保存と特性解析のための新しい技術の出現は、市場拡大にさらに拍車をかけると予想されます。特筆すべきは、市場の主要企業が成長を促進するために共同研究に取り組んでいることです。2021年5月にOpsis Therapeutics、FUJIFILM Cellular Dynamics、Blue Rock Therapeuticsが眼疾患治療用の既製iPSCを開発するために提携したことがその例です。2022年3月にインディアナ大学医療部が主導した研究のように、視力と血管の健康状態を改善するヒトiPS細胞の可能性を示す最近の研究は、2型糖尿病に関連する血管の健康合併症の管理における幹細胞バンクの重要性を強調しています。さらに、凍結保存中の組織の安定性を維持することを目的とした凍結保護剤の研究が進行中であることも、市場成長の起爆剤になると予想されます。
目次
エグゼクティブサマリー
- 市場概要
- 繁栄と衰退
調査手法
- 情報調達
- セカンダリとプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資の分析
- 主要成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
細胞バンクアウトソーシングの世界市場：タイプ別
- 市場概要
- マスター細胞バンクとワーキング細胞バンク
細胞バンクアウトソーシングの世界市場：エンドユーザー別
- 市場概要
- バイオ医薬品会社と受託研究機関（CROS）
細胞バンクアウトソーシングの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Lonza Group Ltd.（スイス）
- SGS SA（スイス）
- Charles River Laboratories International, Inc.（米国）
- WuXi AppTec（中国）
- Eurofins Scientific（ルクセンブルグ）
- Merck KGaA（ドイツ）
- BioReliance Corporation（米国）
- Toxikon Corporation（米国）
- GlobalStem（米国）
- Paragon Bioservices, Inc.（米国）
- BSL Bioservice Scientific Laboratories GmbH（ドイツ）
- ATCC（米国）
- BioOutsource Ltd.（英国）
- ViruSure GmbH（オーストリア）
- Sartorius AG（ドイツ）
- Thermo Fisher Scientific Inc.（米国）
- Covance Inc.（米国）
- TATAA Biocenter AB（スウェーデン）
- CellBank Australia（オーストラリア）
- StemExpress, LLC（米国）
Global Cell Banking Outsourcing Market size was valued at USD 10.60 billion in 2022 and is poised to grow from USD 12.34 billion in 2023 to USD 41.58 billion by 2031, growing at a CAGR of 16.40% during the forecast period (2024-2031).
The global cell banking outsourcing market is poised for substantial growth in the forthcoming years, buoyed by various factors. A significant driver is the advancing techniques in cryopreservation and cell bank preparation, alongside the escalating adoption of stem cell therapies and mounting demand for monoclonal antibodies and efficient biopharmaceuticals. With global enrollments of new trials in advanced cell therapy surging by nearly 30% in the initial quarter of 2020, as reported by CellTrials.org, there's evident growing demand for cell banking services. Furthermore, favorable government initiatives and the advent of novel technologies for cell line storage and characterization are anticipated to further fuel market expansion. Notably, key market players are engaging in research collaborations to drive growth, exemplified by Opsis Therapeutics, FUJIFILM Cellular Dynamics, and Blue Rock Therapeutics joining forces in May 2021 to develop off-the-shelf iPSCs for ocular disease treatment. Recent studies, like the one led by the Indiana University School of Medicine in March 2022, showcasing the potential of human-induced pluripotent stem cells in improving visual acuity and vascular health, underscore the significance of stem cell banking in managing vascular health complications linked to type 2 diabetes. Moreover, ongoing research into cryoprotective agents aimed at preserving tissue stability during cryopreservation is expected to be another catalyst for market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Banking Outsourcing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cell Banking Outsourcing Market Segmental Analysis
Global Cell Banking Outsourcing market is segmented by type, end-user, and region. Based on type, the market can be segmented into master cell banking, and working cell banking. Based on end-user, the market is segmented into biopharmaceutical companies and contract research organizations (CROs). Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Cell Banking Outsourcing Market
The escalating adoption of stem cell therapies stands as a significant catalyst propelling the global cell banking outsourcing market forward. Stem cell therapy, a swiftly advancing sector within regenerative medicine, holds promise in addressing various diseases and disorders. With the expanding demand for such therapies, there arises a pressing need for reliable and top-tier cell lines, thereby fueling the requirement for cell banking services. Consequently, this surge in demand is spurring the growth of the cell banking outsourcing market, as biopharmaceutical firms and CROs pursue streamlined and economical avenues for the production and preservation of these invaluable cell lines.
Restraints in the Global Cell Banking Outsourcing Market
One of the primary challenges facing the global cell banking outsourcing market is the substantial expense associated with cell banking services. The rigorous testing and characterization essential for guaranteeing the safety and quality of cell lines necessitate substantial investments in specialized equipment and infrastructure, consequently elevating service costs. Moreover, stringent regulations enforced by regulatory authorities pertaining to cell line production and storage further contribute to the overall expenses. These high costs might hinder the widespread adoption of such services, particularly in developing regions where healthcare budgets are constrained.
Market Trends of the Global Cell Banking Outsourcing Market
One notable trend in the cell banking outsourcing sector is the rising interest in personalized medicine, which seeks to deliver tailored treatments according to each patient's genetic composition. Achieving this goal involves utilizing cells customized to individual requirements. To meet this demand, cell banking outsourcing firms are directing investments towards technologies capable of producing genetically matched cells for patients. This trend is projected to fuel market expansion, reflecting the growing demand for personalized medical solutions.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Cell Banking Outsourcing Market by Type
- Market Overview
- Master Cell Banking and Working Cell Banking
Global Cell Banking Outsourcing Market by End-User
- Market Overview
- Biopharmaceutical Companies and Contract Research Organizations (Cros).
Global Cell Banking Outsourcing Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SGS SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories International, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi AppTec (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioReliance Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Toxikon Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlobalStem (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Paragon Bioservices, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BSL Bioservice Scientific Laboratories GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ATCC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioOutsource Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ViruSure GmbH (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sartorius AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Covance Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- TATAA Biocenter AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CellBank Australia (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- StemExpress, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
